CD8A and neoplasm: The therapeutic effect, the so called graft-versus-tumor (GVT) effect, can be attributed to donor-derived CD8+ T cells directed against antigens expressed on the recipient tumor cells, including minor histocompatibility antigens (MiHAs) and tumor-associated antigens (TAAs).1,2